Podcasts

Dr. Califf expands on the criticisms and concerns surrounding surrogate endpoints and confirmatory trials within the accelerated approval process, shedding light on the ongoing dialogue between the Administration and manufacturers regarding these crucial trials. He navigates through the intricacies of the Food and Drug Omnibus Reform Act, offering perspectives on the global use of drugs

Drs. Hossein Borghaei and Tony Calles dissect the pivotal abstracts and cutting-edge data unveiled at ESMO 2023, spotlighting the transformative landscape of lung cancer treatment. From exploring innovative immunotherapy combinations to the promising prospects of antibody-drug conjugates, they navigate through the complexities of neo-adjuvant and adjuvant sequencing, shedding light on optimal therapeutic strategies.

Steve Stavs, a “pro biohacker” and “health futurist,” unveils his model to combat chronic diseases by addressing root causes, while exploring Eastern medicine’s approach to preventive care and its current standing in research and empirical evidence for complementary interventions. As a pro biohacker, Stavs shares insights on optimizing whole-body performance and health, highlighting the impact

Ameish Govindarajan, MD, a Hospice and Palliative Medicine fellow at Memorial Sloan Kettering Cancer Center, shares his journey outlined in the Journal of Clinical Oncology’s Art of Oncology piece, “Chasing Milestones,” which sheds light on his personal experience as a patient diagnosed with stage 4 NSCLC.

Chadi is joined by experts Jennifer Wargo, MD, Nazli Dizman, MD, and Sumanta (Monty) Pal, MD, from The University of Texas MD Anderson Cancer Center and City of Hope, to unravel the intricate relationship between the microbiome and cancer.

Dr. Allison Rosenthal, Assistant Professor of Medicine and a driving force behind Mayo Clinic’s Adolescent and Young Adult Cancer Program, candidly shares her personal odyssey as a leukemia survivor during her young adulthood and how this transformative experience steered her career toward advocating for AYA cancer patients.

Dr. Clifford Hudis, the ASCO CEO, shares ASCO’s approach to the continued ABIM-MOC saga. With many oncologists expressing their angst about the MOC process, ASCO, under his leadership, approached the situation methodically, sending a survey to its members to quantify the problem and explore next steps.

Join Chadi as he engages with Petros Grivas, MD, PhD, Professor in the Clinical Research division of Fred Hutchinson Cancer Center, to unravel the groundbreaking updates in bladder cancer revealed at the ESMO Congress.